🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. A study to test how different doses of BI 1703880 in combination with ezabenlimab are tolerated in people with different types of advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced solid tumours

    phase 1 other active

    1 trial

  2. A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours

    phase 1 other active

    1 trial

  3. A study to test how well different doses of BI 764532 are tolerated by people with a tumour in the brain that is positive for DLL3

    Boehringer Ingelheim

    Glioma expressing DLL3

    phase 1 other active

    1 trial

  4. A study to test whether BI 456906 (survodutide) influences the amount of bupropion, caffeine and midazolam in the blood in people with overweight or obesity

    Boehringer Ingelheim

    Overweight, Obesity

    phase 1 other active

    1 trial

  5. A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and neck cancer or liver cancer

    Boehringer Ingelheim

    head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma

    phase 1 other active

    1 trial

  6. A study to test whether treatment with BI 770371 in combination with pembrolizumab with or without cetuximab helps people with head and neck cancer compared with pembrolizumab alone

    Boehringer Ingelheim

    Head and neck squamous cell carcinoma

    phase 1 other active

    1 trial

  7. A three-part trial in healthy volunteers to find out how long icotrokinra stays in and acts on the body when administered as different tablet formulations and under different food conditions

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  8. A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lung cancer that cannot be completely cured.

    CureVac AG

    metastatic squamous non-small cell lung cancer

    phase 1 other active

    1 trial

  9. A trial to learn about how multiple doses of itraconazole change how AZD5004 moves throughout the body over time in healthy adults and how multiple doses of AZD5004 change how ethinyl estradiol and levonorgestrel move throughout the body overtime in healthy female adults

    AstraZeneca AB

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  10. A trial to learn how ceralasertib affects the way certain medications move throughout the body over time and how safe it is to use ceralasertib with these medications in adults with advanced solid tumors

    AstraZeneca AB

    Advanced solid tumour

    phase 1 other active

    1 trial

  11. A trial to learn how much budesonide, glycopyrronium, and formoterol fumarate (BGF) gets into and moves throughout the body when it is taken with hydrofluoroolefin (HFO) compared to when it is taken with hydrofluoroalkane (HFA) in healthy adults

    AstraZeneca AB

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  12. A trial to learn how safe AZD4063 is, how it moves throughout the body over time, and how it affects the levels of PLN mRNA in adults with dilated cardiomyopathy because of an R14del mutation in the PLN gene

    AstraZeneca AB

    PLN R14del Dilated Cardiomyopathy

    phase 1 other active

    1 trial

  13. A trial to learn how safe AZD5335 is and if a drug called itraconazole changes how AZD5335 moves through the body over time in adults with ovarian, peritoneal, or fallopian tube cancer

    AstraZeneca AB

    Ovarian cancer Primary peritoneal cancer Fallopian tube cancer

    phase 1 other active

    1 trial

  14. A trial to learn how well different doses of andexanet alfa work and how they affect blood clotting throughout the body in healthy adults who have taken an FXa inhibitor

    AstraZeneca AB

    Healthy Volunteers

    phase 1 other active

    1 trial

  15. A trial to learn if AZD5335 alone and in combination with other treatments is safe and effective and how it moves through the body in people with solid tumors

    AstraZeneca AB

    Platinum-resistant recurrent (PRR) ovarian cancer, Platinum-sensitive recurrent (PSR) ovarian cancer, Lung Adenocarcinoma, and endometrial cancer.

    phase 1 other active

    1 trial

  16. A trial to learn if itraconazole and carbamazepine affect how AZD5462 moves throughout the bodies of healthy adults

    AstraZeneca AB

    Chronic Heart Failure

    phase 1 other active

    1 trial

  17. A two-part trial in healthy volunteers to find out how long JNJ-77242113 stays in and acts on the body when administered as different tablet formulations and under different food and water conditions, and to assess the acceptability profile (taste, palatability, and smell) of JNJ-77242113 formulations.

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  18. ADCT-301

    ADC Therapeutics SA

    Head and Neck Cancer Squamous Cell Carcinoma

    phase 1 small molecule terminated

    1 trial

  19. ADME: A Study to Understand What the Body does to the Study Compound Called PF-07220060 When Taken by Healthy Adults.

    Pfizer Australia Pty Ltd

    metastatic/advanced breast cancer

    phase 1 other active

    1 trial

  20. ALLO-329

    Allogene Therapeutics

    Systemic Lupus Erythematosus (With and Without Nephritis)

    phase 1 gene therapy active

    1 trial

  21. AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

    Amgen

    Thoracic tumors with homozygous MTAP-deletion

    phase 1 other active

    1 trial

  22. AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion – Master Protocol

    Amgen

    Gastrointestinal tract, biliary tract, or pancreatic cancers with homozygous methylthioadenosine phosphorylase (MTAP)-deletion

    phase 1 other active

    1 trial

  23. APTO-253

    Aptose Biosciences

    Acute Myelogenous Leukemia in Relapse

    phase 1 small molecule terminated

    1 trial

  24. ATA3219

    Evidence Based Cataract Study Group

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources